# Rollover Study to Provide Continued Treatment for Participants With B-Cell Malignancies Previously Enrolled in Studies of Parsaclisib (INCB050465)

Source: https://onco.cc/trials/nct04509700/  
OnCo record `nct04509700` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial of Parsaclisib, Ruxolitinib and Ibrutinib in advanced solid tumours, run by Incyte Corporation, active and no longer recruiting.

## Summary

Rollover Study to Provide Continued Treatment for Participants With B-Cell Malignancies Previously Enrolled in Studies of Parsaclisib (INCB050465) is a phase 2 interventional study registered as NCT04509700 by Incyte Corporation, with 112 participants enrolled, started 2020-08-03 and due to reach its primary completion in 2026-11-05. Interventions recorded: Parsaclisib, parsaclisib + itacitinib, parsaclisib + ruxolitinib and parsaclisib + ibrutinib.

## Fields

- Kind: Trial
- Status: active
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT04509700
- Phase: 2
- Setting: A Phase 2, Open-Label, Multicenter, Rollover Study to Provide Continued Treatment for Participants With B-Cell Malignancies Previously Enrolled in Studies of Parsaclisib (INCB050465)
- Sponsor: Incyte Corporation
- Enrolled: 112

## Sources

- ClinicalTrials.gov NCT04509700: https://clinicaltrials.gov/study/NCT04509700

## Connected records

- cancers: [Metastatic cancer (cancer that has spread)](https://onco.cc/cancers/metastatic-cancer/)
- drugs: [Ibrutinib](https://onco.cc/drugs/ibrutinib/), [Parsaclisib](https://onco.cc/drugs/parsaclisib/), [Ruxolitinib](https://onco.cc/drugs/ruxolitinib/)
- companies: [Incyte](https://onco.cc/companies/incyte/)

---
JSON: https://onco.cc/api/v1/entities/nct04509700.json